Abstract
BackgroundInfliximab is well-established tumor necrosis factor α inhibitor in management of rheumatoid arthritis (RA). It has shown efficacy in many randomized controlled clinical trials and registries.ObjectivesTo assess the efficacy of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
